EN DE

Almujtama Alraida Medical Co (9592) Fair Value & Analysis

Healthcare · SA · Market cap 217M SAR

AA Almujtama Alraida Medical Co 9592 · SR
Price22.89 SAR
Fair Value15.02 SAR
Upside-34.4%
Quality47/100
Healthy Growth
Thin margins · 0.0% net margin
generates free cash flow
Trails peers (3/12)
Watch Almujtama Alraida Medical Co for free, get notified when fair value or trend changes. Watch for free
Evidence: High Range 13.25 SAR – 18.77 SAR Share as image

Fair value as of: Aug 1, 2026

From 23 valuation models · updated today

Share price +2.6% over the past month.

What matters now

  • The price sits above even our optimistic bull case (18.77 SAR). The favourable scenario is already priced in.
  • Solid but not exceptional quality (47/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (12 months)

32.63 SAR 22.00 SAR Fair Value 15.02 SAR Aug 2025 Jul 2026

12‑month range 22.00 SAR – 32.63 SAR · fair‑value band 13.25 SAR – 18.77 SAR · the 22.89 SAR price screens above the 15.02 SAR fair value. As of Aug 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

Almujtama Alraida Medical Co (9592) currently trades at 22.89 SAR, while our model-based Fair Value estimate is 15.02 SAR, implying the stock looks roughly 34.4% overvalued today. We read business quality at 47/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Net debt stands at 168M SAR. The stock trades on a trailing P/E of 26.0. Fundamentals as of Aug 1, 2026

Our scenario range runs from 13.25 SAR (bear case) to 18.77 SAR (bull case); at 22.89 SAR, the current price sits above that range. The share trades about 31% below its 52-week high and 6% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 37% fair-value upside, at -34%, 9592 screens richer than that median.

Key figures & financial health

Free cash flow 25.0M SAR FY2025
P/E ratio 26.0
EPS (TTM) 0.8800 SAR
Net debt 168M SAR FY2024

Figures from reported company fundamentals · as of Aug 1, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 47/100
Profitability 39
Quality Growth 31
Cashflow 66
Fin. Strength 31
Investment 71
Low Volatility 62
Momentum 17
52W Momentum 8
Net Issuance 82

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Almujtama Alraida Medical Co. operates pharmacies in Saudi Arabia. The company provides pharmaceutical services; and a magazine related to medical and pharmaceutical health field. It also offers its products through online. The company was founded in 2001 and is based in Jeddah, Saudi Arabia.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Almujtama Alraida Medical Co reported revenue of 455M SAR in FY2025 versus 304M SAR in FY2021, a compound +10.5%/yr. Reported net income was 8.4M SAR in FY2025, compounding +1.8%/yr from FY2021.

Revenue +10.5%/yr
FY21 304M SAR
FY22 367M SAR
FY23 408M SAR
FY24 431M SAR
FY25 455M SAR
Net income +1.8%/yr
FY21 7.8M SAR
FY22 19.1M SAR
FY23 11.4M SAR
FY24 7.9M SAR
FY25 8.4M SAR

Is 9592 fairly valued? → Check now

Share or link this analysis
📋 Free embed code + live data for your site

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Almujtama Alraida Medical Co Fair Value". https://www.fairvalue-calculator.com/stock/9592

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Pharmaceutical Retailers stocks, each showing price versus our Fair Value estimate (as of Aug 1, 2026).

Stock Price Fair Value vs Fair Value
JD Health International Inc JDHIY $4.55 $8.78 +93%
Alibaba Health Information Technology Limited ALBBY $8.27 $6.61 -20%
Raia Drogasil S.A RADL3 R$16.79 R$20.39 +21%
Yifeng Pharmacy Chain Co 603939 ¥19.75 ¥40.59 +106%
Clicks Group CLCGY $27.97 $34.29 +23%
Sugi Holdings SGIPF $16.29 $32.19 +98%
Corporativo Fragua, S.A. CGSBF $29.66 $40.69 +37%
DaShenLin Pharmaceutical Group 603233 ¥16.68 ¥19.21 +15%
LBX Pharmacy Chain Joint Stock Company 603883 ¥11.74 ¥10.57 -10%
Redcare Pharmacy NV SHPPF $64.80 $143.56 +122%

Compare Almujtama Alraida Medical Co with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Almujtama Alraida Medical Co (9592) overvalued or undervalued?
As of Aug 1, 2026, our model estimates a fair value of 15.02 SAR versus a price of 22.89 SAR, about −34% (overvalued).
What is the fair value of 9592?
Our model-based fair value for Almujtama Alraida Medical Co is 15.02 SAR (as of Aug 1, 2026), built from audited fundamentals. The current price is 22.89 SAR.
What is the quality score of 9592?
Almujtama Alraida Medical Co has a Quality Score of 47/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.
What is the net profit margin of 9592?
The net profit margin of Almujtama Alraida Medical Co is about 0.0%, meaning it keeps roughly 0.0% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Almujtama Alraida Medical Co and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.